

according to GB/T 16483 and GB/T 17519

Abamectin / Fluazuron Formulation

Vers 5.4	sion	Revision Date: 2021/08/27		S Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12				
1. PI	1. PRODUCT AND COMPANY IDENTIFICATION								
	Produc	t name	:	Abamectin / Flua	zuron Formulation				
	Manufa	acturer or supplier's d	letai	ls					
	Compa	ny	:	MSD					
	Addres	S	:	No. 485 Jing Tai Pu Tuo District -	Road Shanghai - China 200331				
	Telepho	one	:	+1-908-740-4000)				
	Emerge	ency telephone number	• :	86-571-87268110	0				
	E-mail a	address	:	EHSDATASTEW	ARD@msd.com				
	Recommended use of the chemical and restrictions on use								

2. HAZARDS IDENTIFICATION

Recommended use

Emergency Overview

Appearance Colour Odour	liquid No data available No data available
	mful if swallowed or if inhaled. Causes skin irritation. May auses serious eye irritation. May cause respiratory irritation

: Veterinary product

cause an allergic skin reaction. Causes serious eye irritation. May cause respiratory irritation. May cause drowsiness or dizziness. May damage the unborn child. May cause damage to organs through prolonged or repeated exposure. Very toxic to aquatic life with long lasting effects.

GHS Classification

Flammable liquids	:	Category 3
Acute toxicity (Oral)	:	Category 4
Acute toxicity (Inhalation)	:	Category 4
Skin corrosion/irritation	:	Category 2
Serious eye damage/eye irri- tation	:	Category 2A
Skin sensitisation	:	Category 1
Reproductive toxicity	:	Category 1B
Specific target organ toxicity - single exposure	:	Category 3
Specific target organ toxicity -	:	Category 2



according to GB/T 16483 and GB/T 17519

Abamectin / Fluazuron Formulation

Version 5.4	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
repe	ated exposure		
Shor haza	t-term (acute) aquatic ırd	: Category 1	
Long haza	p-term (chronic) aquatic rd	: Category 1	
GHS	label elements		
Haza	ard pictograms		
Sign	al word	: Danger	
Haza	ard statements	H302 + H332 H315 Causes H317 May ca H319 Causes H335 May ca H336 May ca H360D May ca H373 May ca peated expos	able liquid and vapour. 2 Harmful if swallowed or if inhaled. 5 skin irritation. 1 use an allergic skin reaction. 5 serious eye irritation. 1 use respiratory irritation. 1 use drowsiness or dizziness. 1 damage the unborn child. 1 use damage to organs through prolonged or re- sure. 1 xic to aquatic life with long lasting effects.
Prec	autionary statements	P202 Do not and understo P210 Keep a No smoking. P233 Keep c P241 Use ex ment. P242 Use on P243 Take pi P260 Do not P264 Wash s P270 Do not P271 Use on P272 Contan the workplace P273 Avoid r P280 Wear p tion/ face pro	way from heat/ sparks/ open flames/ hot surfaces ontainer tightly closed. plosion-proof electrical/ ventilating/ lighting equip- ly non-sparking tools. recautionary measures against static discharge. breathe mist or vapours. skin thoroughly after handling. eat, drink or smoke when using this product. ly outdoors or in a well-ventilated area. hinated work clothing should not be allowed out o e. elease to the environment. rotective gloves/ protective clothing/ eye protec- tection.
		CENTER/ do P303 + P361	+ P330 IF SWALLOWED: Call a POISON ctor if you feel unwell. Rinse mouth. + P353 IF ON SKIN (or hair): Take off immediate nated clothing. Rinse skip with water/ shower

ly all contaminated clothing. Rinse skin with water/ shower.

according to GB/T 16483 and GB/T 17519



Abamectin / Fluazuron Formulation

Version 5.4	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
		and keep comfo doctor if you fee P305 + P351 + for several minu easy to do. Con P308 + P313 IF attention. P333 + P313 If vice/ attention. P337 + P313 If tention.	P338 IF IN EYES: Rinse cautiously with water ites. Remove contact lenses, if present and tinue rinsing. exposed or concerned: Get medical advice/ skin irritation or rash occurs: Get medical ad- eye irritation persists: Get medical advice/ at- ake off contaminated clothing and wash it before
		Storage: P403 + P235 St P405 Store lock	ore in a well-ventilated place. Keep cool. ed up.

Disposal:

P501 Dispose of contents/ container to an approved waste disposal plant.

Physical and chemical hazards

Flammable liquid and vapour.

Health hazards

Harmful if swallowed. Harmful if inhaled. Causes skin irritation. Causes serious eye irritation. May cause an allergic skin reaction. May damage the unborn child. May cause respiratory irritation. May cause drowsiness or dizziness. May cause damage to organs through prolonged or repeated exposure.

Environmental hazards

Very toxic to aquatic life. Very toxic to aquatic life with long lasting effects.

Other hazards which do not result in classification


Vapours may form explosive mixture with air.

3. COMPOSITION/INFORMATION ON INGREDIENTS

Substance / Mixture : Mixture

Components

Chemical name	CAS-No.	Concentration (% w/w)
Propan-2-ol	67-63-0	>= 30 -< 50
N-Methyl-2-pyrrolidone	872-50-4	>= 30 -< 50
Poly[oxy(methyl-1,2-ethanediyl)], α-(1- oxotetradecyl)-ω-(phenylmethoxy)-	642443-86-5	>= 20 -< 30
Fluazuron	86811-58-7	>= 2.5 -< 10
abamectin (combination of avermectin B1a and avermectin B1b) (ISO)	71751-41-2	>= 1 -< 2.5
7-Oxabicyclo[4.1.0]hept-3-ylmethyl 7- oxabicyclo[4.1.0]heptane-3-carboxylate	2386-87-0	>= 1 -< 2.5





Version 5.4	Revision Date: 2021/08/27	SDS Number: 800398-00018			2021/04/26 2016/07/12
2,6-Di	i-tert-butyl-p-cresol		128-37-0		>= 0.1 -< 0.25
I. FIRST A					
Gene	ral advice	vice immed	iately.		nwell, seek medical ad- s of doubt seek medical
lf inha	aled	If not breat	emove to fresh ai ning, give artificial is difficult, give o	l respirati	on.
In cas	e of skin contact	: In case of c for at least and shoes. Get medica Wash cloth	contact, immediate 15 minutes while	removing	skin with plenty of water contaminated clothing
In cas	e of eye contact	for at least	15 minutes. o, remove contac	-	eyes with plenty of water worn.
lf swa	llowed	: If swallowe Get medica Rinse mout	d, DO NOT induc Il attention. h thoroughly with	water.	g. nconscious person.
	important symptoms ffects, both acute and ed	: Harmful if s Causes ski May cause Causes ser May cause May cause May damag	wallowed or if inh n irritation. an allergic skin re ious eye irritation respiratory irritati drowsiness or diz ge the unborn chil	aled. eaction. on. zziness. d.	n prolonged or repeated
	ction of first-aiders	: First Aid read and use the when the p	e recommended p otential for expos	ersonal p ure exists	
	to physician	: Treat symp	tomatically and s	upportive	Iy.
	ble extinguishing media	: Water spra	v		
		Alcohol-res Carbon dio Dry chemic	istant foam xide (CO2) al		
media		: High volum	-	_	
Speci fightin	fic hazards during fire- Ig	fire. Flash back	a solid water stre possible over cor ay form explosive	nsiderable	



according to GB/T 16483 and GB/T 17519

Abamectin / Fluazuron Formulation

Version 5.4	Revision Date: 2021/08/27		0S Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
			Exposure to comb	oustion products may be a hazard to health.
Haza ucts	rdous combustion prod-	:	Carbon oxides Nitrogen oxides (I Chlorine compour Fluorine compour	nds
ods	fic extinguishing meth-	:	cumstances and t Use water spray t Remove undamag so. Evacuate area.	measures that are appropriate to local cir- he surrounding environment. o cool unopened containers. ged containers from fire area if it is safe to do
	al protective equipment efighters	:	In the event of fire Use personal prot	e, wear self-contained breathing apparatus. ective equipment.
6. ACCIDE	ENTAL RELEASE MEAS	SUF	RES	
tive e	onal precautions, protec- quipment and emer- / procedures	:		
Enviro	onmental precautions	:	Prevent spreading barriers). Retain and dispos	akage or spillage if safe to do so. g over a wide area (e.g. by containment or oil e of contaminated wash water. should be advised if significant spillages
	ods and materials for inment and cleaning up	:	Suppress (knock of spray jet. For large spills, priment to keep mate be pumped, store Clean up remaining bent. Local or national riposal of this mate employed in the cimine which regular Sections 13 and 1	s should be used. absorbent material. down) gases/vapours/mists with a water ovide dyking or other appropriate contain- erial from spreading. If dyked material can recovered material in appropriate container. og materials from spill with suitable absor- egulations may apply to releases and dis- rial, as well as those materials and items leanup of releases. You will need to deter- tions are applicable. 5 of this SDS provide information regarding tional requirements.

7. HANDLING AND STORAGE

Handling	
Technical measures	: See Engineering measures under EXPOSURE CONTROLS/PERSONAL PROTECTION section.
Local/Total ventilation	: If sufficient ventilation is unavailable, use with local exhaust

according to GB/T 16483 and GB/T 17519



Abamectin / Fluazuron Formulation

Version 5.4	Revision Date: 2021/08/27		DS Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12		
Advice on safe handling		:	 ventilation. Use explosion-proof electrical, ventilating and lighting ment. Do not get on skin or clothing. Do not breathe mist or vapours. Do not swallow. Do not get in eyes. Wash skin thoroughly after handling. Handle in accordance with good industrial hygiene ar practice, based on the results of the workplace exposisessment Non-sparking tools should be used. Keep container tightly closed. Already sensitised individuals should consult their phyregarding working with respiratory irritants or sensitise Keep away from heat, hot surfaces, sparks, open flan other ignition sources. No smoking. Take precautionary measures against static discharg Do not eat, drink or smoke when using this product. Take care to prevent spills, waste and minimize releation. 			
Avo	vidance of contact	:	environment. Oxidizing agents			
Sto	rage					
Cor	nditions for safe storage	:	Store locked up. Keep tightly close Keep in a cool, w Store in accordar	abelled containers. ed. ell-ventilated place. ice with the particular national regulations. neat and sources of ignition.		
Mat	terials to avoid	:	Do not store with Self-reactive subs Organic peroxide Oxidizing agents Flammable gases Pyrophoric liquids Pyrophoric solids	the following product types: stances and mixtures s s tances and mixtures		
Pad	kaging material	:	Unsuitable mater	al: None known.		

8. EXPOSURE CONTROLS/PERSONAL PROTECTION

Components with workplace control parameters

Components	CAS-No.	Value type	Control parame-	Basis
		(Form of	ters / Permissible	
		exposure)	concentration	
Propan-2-ol	67-63-0	PC-TWA	350 mg/m3	CN OEL
		PC-STEL	700 mg/m3	CN OEL
		TWA	200 ppm	ACGIH
		STEL	400 ppm	ACGIH



according to GB/T 16483 and GB/T 17519

Abamectin / Fluazuron Formulation

Ver 5.4	sion	Revision Date: 2021/08/27	SDS Number: 800398-00018		t issue: 2021/04/26 t issue: 2016/07/12	
	Fluazu	ron	86811-58-7	TWA	60 µg/m3 (OEB 3)	Internal
				Wipe limit	600 µg/ 100cm2	Internal
	averme	ctin (combination of ectin B1a and avermec-) (ISO)	71751-41-2	TWA	15 μg/m3 (OEB 3)	Internal
				Wipe limit	150 µg/100 cm ²	Internal
	2,6-Di-	tert-butyl-p-cresol	128-37-0	TWA (Inhal- able fraction and vapor)	2 mg/m3	ACGIH

Biological occupational exposure limits

Components	CAS-No.	Control parameters	Biological specimen	Sam- pling time	Permissible concentra- tion	Basis
N-Methyl-2-pyrrolidone	872-50-4	5-Hydroxy- N-methyl-2- pyrrolidone	Urine	End of shift (As soon as possible after exposure ceases)	100 mg/l	ACGIH BEI
Propan-2-ol	67-63-0	Acetone	Urine	End of shift at end of work- week	40 mg/l	ACGIH BEI

Engineering measures	:	Use appropriate engineering controls and manufacturing technologies to control airborne concentrations (e.g., drip- less quick connections). All engineering controls should be implemented by facility design and operated in accordance with GMP principles to protect products, workers, and the environment. Containment technologies suitable for controlling compounds are required to control at source and to prevent migration of the compound to uncontrolled areas (e.g., open-face con- tainment devices). Minimize open handling.
		Use explosion-proof electrical, ventilating and lighting equip- ment.
Personal protective equipme	ent	
Respiratory protection Filter type	:	If adequate local exhaust ventilation is not available or expo- sure assessment demonstrates exposures outside the rec- ommended guidelines, use respiratory protection. Combined particulates and organic vapour type
Eye/face protection	:	Wear safety glasses with side shields or goggles. If the work environment or activity involves dusty conditions, mists or aerosols, wear the appropriate goggles. Wear a faceshield or other full face protection if there is a potential for direct contact to the face with dusts, mists, or aerosols.
Skin and body protection	:	Work uniform or laboratory coat.

according to GB/T 16483 and GB/T 17519



Abamectin / Fluazuron Formulation

Version 5.4	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
		task being posable sui	body garments should be used based upon the performed (e.g., sleevelets, apron, gauntlets, dis- ts) to avoid exposed skin surfaces. rriate degowning techniques to remove potentially ed clothing.
Hand	l protection		
М	aterial	: Chemical-re	esistant gloves
R	emarks		ouble gloving. Take note that the product is flam- ch may impact the selection of hand protection.
Hygie	ene measures	: If exposure eye flushing ing place. When using Contaminat workplace. Wash conta The effectiv engineering appropriate industrial hy	to chemical is likely during typical use, provide g systems and safety showers close to the work- g do not eat, drink or smoke. The work clothing should not be allowed out of the aminated clothing before re-use. The operation of a facility should include review of g controls, proper personal protective equipment, degowning and decontamination procedures, regiene monitoring, medical surveillance and the inistrative controls.

9. PHYSICAL AND CHEMICAL PROPERTIES

Appearance	:	liquid
Colour	:	No data available
Odour	:	No data available
Odour Threshold	:	No data available
рН	:	No data available
Melting point/freezing point	:	No data available
Initial boiling point and boiling range	:	No data available
Flash point	:	28 °C
Flash point Evaporation rate	:	28 °C No data available
	-	
Evaporation rate	:	No data available
Evaporation rate Flammability (solid, gas)	:	No data available Not applicable

according to GB/T 16483 and GB/T 17519



Abamectin / Fluazuron Formulation

Version 5.4	Revision Date: 2021/08/27		S Number:)398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
flamma	ability limit			
Vapou	r pressure	:	No data available	9
Relativ	ve vapour density	:	No data available	9
Relativ	e density	:	No data available	9
Densit	y	:	No data available	9
	lity(ies) ter solubility	:	No data available	9
	on coefficient: n- I/water	:	Not applicable	
	gnition temperature	:	No data available	9
Decom	position temperature	:	No data available	9
Viscos Vise	ity cosity, kinematic	:	No data available	9
Explos	ive properties	:	Not explosive	
Oxidizi	ng properties	:	The substance o	r mixture is not classified as oxidizing.
Molecu	ular weight	:	No data available	9
Particle	e size	:	Not applicable	

10. STABILITY AND REACTIVITY

Reactivity Chemical stability Possibility of hazardous reac- tions	:	Not classified as a reactivity hazard. Stable under normal conditions. Flammable liquid and vapour. Vapours may form explosive mixture with air. Can react with strong oxidizing agents.
Conditions to avoid Incompatible materials Hazardous decomposition products	:	Heat, flames and sparks. Oxidizing agents No hazardous decomposition products are known.

11. TOXICOLOGICAL INFORMATION

Exposure routes	: Inhalation
-	Skin contact
	Ingestion
	Eye contact

Acute toxicity

Harmful if swallowed or if inhaled.

according to GB/T 16483 and GB/T 17519



Abamectin / Fluazuron Formulation

sion	Revision Date: 2021/08/27		0S Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
<u>Produ</u>	<u>uct:</u>			
Acute	oral toxicity	:	Acute toxicity e Method: Calcul	stimate: 1,824 mg/kg ation method
Acute	inhalation toxicity	:	Acute toxicity e Exposure time: Test atmosphe Method: Calcul	re: dust/mist
Acute	dermal toxicity	:	Acute toxicity e Method: Calcul	stimate: > 5,000 mg/kg ation method
Comp	oonents:			
Propa	an-2-ol:			
Acute	oral toxicity	:	LD50 (Rat): > 5	5,000 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 2 Exposure time: Test atmosphe	6 h
Acute	dermal toxicity	:	LD50 (Rabbit):	> 5,000 mg/kg
N-Me	thyl-2-pyrrolidone:			
	oral toxicity	:	LD50 (Rat): 4,1	50 mg/kg
Acute	inhalation toxicity	:	LC50 (Rat): > 5 Exposure time: Test atmosphe Method: OECD	4 h
Acute	dermal toxicity	:	LD50 (Rat): > 5	i,000 mg/kg
Polví	oxv(methyl-1 2-ethai	nedivl)] α-(1-oxotetra	decyl)-ω-(phenylmethoxy)-:
	oral toxicity	-	LD50 (Rat): > 1	
Fluaz	uron:			
Acute	oral toxicity	:	LD50 (Rat): > 5 Method: OECD	i,000 mg/kg Test Guideline 401
Acute	inhalation toxicity	:	LC50 (Rat): > 6 Exposure time: Test atmosphe Method: OECD	4 h
Acute	dermal toxicity	:	LD50 (Rat): > 2 Method: OECD	2,000 mg/kg Test Guideline 402

Acute oral toxicity

10 / 29

: LD50 (Rat): 24 mg/kg

according to GB/T 16483 and GB/T 17519



Versior 5.4	n Revision Date: 2021/08/27		Number: 98-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
		I	.D50 (Mouse): 10	ma/ka
		L	DLo (Monkey): 24 Symptoms: Dilatat	4 mg/kg
Ac	ute inhalation toxicity	: L E	C50 (Rat): 0.023 xposure time: 4 h est atmosphere:	mg/l
Ac	cute dermal toxicity		.D50 (Rat): 330 m .D50 (Rabbit): 2,0	
		L	.D50 (Rabbil). 2,0	oo mg/kg
				4.1.0]heptane-3-carboxylate:
Ac	ute oral toxicity		.D50 (Rat, male): lethod: OECD Te	2,959 - 5,000 mg/kg st Guideline 401
Ac	ute inhalation toxicity	E T N A	C50 (Rat): >= 5.1 exposure time: 4 h est atmosphere: Method: OECD Te assessment: The s on toxicity	u dust/mist
Ac	ute dermal toxicity	N A	D50 (Rat): > 2,00 /lethod: OECD Te /ssessment: The s pxicity	
2.0	6-Di-tert-butyl-p-cresol:			
	ute oral toxicity		D50 (Rat): > 6,00 lethod: OECD Te	
Ac	ute dermal toxicity	N A	D50 (Rat): > 2,00 /lethod: OECD Te \ssessment: The s oxicity	0 mg/kg st Guideline 402 substance or mixture has no acute dermal
•	tin corrosion/irritation			
<u>Cc</u>	omponents:			
Pr	opan-2-ol:			
Sp	pecies esult		Rabbit Io skin irritation	
N-	Methyl-2-pyrrolidone:			
	esult	: 8	Skin irritation	




according to GB/T 16483 and GB/T 17519

rsion	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
Poly[d	oxy(methyl-1,2-etha	nediyl)], α-(1-oxotetr	adecyl)-ω-(phenylmethoxy)-:
Specie	es	: Rabbit	
Result	t	: Mild skin irrita	tion
Fluaz	uron:		
Specie	es	: Rabbit	
Metho	bd	: OECD Test G	uideline 404
Result	t	: No skin irritati	on
abam	ectin (combination	of avermectin B1a a	nd avermectin B1b) (ISO):
Specie	es	: Rabbit	
Result	t	: No skin irritati	on
7-Oxa	bicyclo[4.1.0]hept-3	3-ylmethyl 7-oxabicy	clo[4.1.0]heptane-3-carboxylate:
Specie	es	: Rabbit	
Metho		: OECD Test G	
Result	t	: No skin irritati	on
2,6-Di	i-tert-butyl-p-cresol:		
Specie		: Rabbit	
Metho		: OECD Test G	
Result		: No skin irritati	
Rema	irks	: Based on data	a from similar materials
	us eye damage/eye		
Cause	es serious eye irritatio	on.	
<u>Comp</u>	oonents:		
-	an-2-ol:		
Specie		: Rabbit	
		: Initiation to ev	
Result	t		es, reversing within 21 days
N-Met	thyl-2-pyrrolidone:		es, reversing within 21 days
N-Met Specie	t hyl-2-pyrrolidone: es	: Rabbit	
N-Met	t hyl-2-pyrrolidone: es	: Rabbit	es, reversing within 21 days es, reversing within 21 days
N-Met Specie Result Poly[6	t hyl-2-pyrrolidone: es t oxy(methyl-1,2-etha	: Rabbit : Irritation to ey nediyl)], α-(1-oxotetr	
N-Met Specie Result Poly[e Specie	t hyl-2-pyrrolidone: es t oxy(methyl-1,2-etha es	: Rabbit : Irritation to ey nediyl)], α-(1-oxotetr : Rabbit	es, reversing within 21 days radecyl)-ω-(phenylmethoxy)-:
N-Met Specie Result Poly[6	t hyl-2-pyrrolidone: es t oxy(methyl-1,2-etha es	: Rabbit : Irritation to ey nediyl)], α-(1-oxotetr	es, reversing within 21 days radecyl)-ω-(phenylmethoxy)-:
N-Met Specie Result Poly[e Specie	t hyl-2-pyrrolidone: es t oxy(methyl-1,2-etha es t	: Rabbit : Irritation to ey nediyl)], α-(1-oxotetr : Rabbit	es, reversing within 21 days radecyl)-ω-(phenylmethoxy)-:
N-Met Specie Result Poly[e Specie Result Fluaze	thyl-2-pyrrolidone: es t oxy(methyl-1,2-etha es t uron: es	: Rabbit : Irritation to ey nediyl)], α-(1-oxotetr : Rabbit : No eye irritatio : Rabbit	es, reversing within 21 days radecyl)-ω-(phenylmethoxy)-: on
N-Met Specie Result Poly[e Result Fluaz	thyl-2-pyrrolidone: es t oxy(methyl-1,2-etha es t uron: es	: Rabbit : Irritation to ey nediyl)], α-(1-oxotetr : Rabbit : No eye irritatio	es, reversing within 21 days radecyl)-ω-(phenylmethoxy)-: on



according to GB/T 16483 and GB/T 17519

Version 5.4	Revision Date: 2021/08/27		S Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
aban Spec Resu	cies	of ave	r mectin B1a and Rabbit Mild eye irritatior	avermectin B1b) (ISO):
7-Ox	abicyclo[4.1.0]hept-	3-ylme	thyl 7-oxabicyclo	o[4.1.0]heptane-3-carboxylate:
Spec		:	Rabbit	
Resu		:	No eye irritation	
Meth	od	:	OECD Test Guid	Ieline 405
)i-tert-butyl-p-cresol	:		
Spec		:	Rabbit	
Resu Meth		:	No eye irritation OECD Test Guid	Iolina 405
Rema				om similar materials
Rom		•		
Resp	piratory or skin sens	itisatio	n	
-	sensitisation cause an allergic skin	reactio	'n	
-	-		<i>и</i> 1.	
•	piratory sensitisation			
Not c	classified based on av	ailable	information.	
<u>Com</u>	ponents:			
Prop	an-2-ol:			
Test	Туре	:	Buehler Test	
	sure routes	:	Skin contact	
Spec		:	Guinea pig	
Meth Resu		:	OECD Test Guid	leline 406
Resu	in and a second s		negative	
	ethyl-2-pyrrolidone:			
	Туре	:	Local lymph nod	e assay (LLNA)
•	sure routes	:	Skin contact	
Spec Meth		:	Mouse OECD Test Guid	leline 120
Resu		:	negative	
Rema		:		om similar materials
Polv	[oxv(methyl-1.2-etha	anedivl)]. α-(1-oxotetrad	ecyl)-ω-(phenylmethoxy)-:
Test				sult patch test (HRIPT)
	sure routes	÷	Skin contact	
Resu		:	negative	
Flua	zuron:			
	sure routes	:	Skin contact	
Spec		:	Guinea pig	
Resu		:	negative	






	2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
abam	nectin (combination	of avermectin B1a a	nd avermectin B1b) (ISO):
Test ⁻	Туре	: Maximisation	Test
	sure routes	: Skin contact	
Resu	lt	: Not a skin sen	isitizer.
7-0x a	abicyclo[4.1.0]hept-	3-ylmethyl 7-oxabicy	clo[4.1.0]heptane-3-carboxylate:
Test ⁻		: Maximisation	
	sure routes	: Skin contact	
Speci		: Guinea pig	
Resu		: positive	
Asses	ssment	: Probability or	evidence of skin sensitisation in humans
2,6-D	i-tert-butyl-p-cresol	:	
Test ⁻	Туре	: Human repeat	t insult patch test (HRIPT)
	sure routes	: Skin contact	,
Speci	ies	: Humans	
Resu	lt	: negative	
Not c	n cell mutagenicity lassified based on av ponents:	ailable information.	
Prop	an-2-ol:		
-	toxicity in vitro	: Test Type: Ba Result: negati	cterial reverse mutation assay (AMES) ve
		Test Type: In Result: negati	vitro mammalian cell gene mutation test ve
Geno	toxicity in vivo	cytogenetic as	
Geno	toxicity in vivo	cytogenetic as Species: Mous	ssay) se bute: Intraperitoneal injection
	toxicity in vivo	cytogenetic as Species: Mous Application Ro	ssay) se bute: Intraperitoneal injection
N-Me	·	cytogenetic as Species: Mous Application Ro Result: negation : Test Type: Ba	ssay) se bute: Intraperitoneal injection ve cterial reverse mutation assay (AMES) D Test Guideline 471
N-Me	thyl-2-pyrrolidone:	cytogenetic as Species: Mous Application Ro Result: negation : Test Type: Ba Method: OECI Result: negation Test Type: In	ssay) se bute: Intraperitoneal injection ve cterial reverse mutation assay (AMES) D Test Guideline 471 ve vitro mammalian cell gene mutation test D Test Guideline 476
N-Me	thyl-2-pyrrolidone:	cytogenetic as Species: Mous Application Ro Result: negation : Test Type: Ba Method: OECI Result: negation Test Type: In Method: OECI Result: negation Test Type: In Method: OECI Result: negation	ssay) se bute: Intraperitoneal injection ve cterial reverse mutation assay (AMES) D Test Guideline 471 ve vitro mammalian cell gene mutation test D Test Guideline 476 ve IA damage and repair, unscheduled DNA syn malian cells (in vitro)

according to GB/T 16483 and GB/T 17519




Version 5.4	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
		cytogenetic ass Species: Mouse Application Rou Method: OECD Result: negative	te: Ingestion Test Guideline 474
		cytogenetic test Species: Hamst Application Rou	te: Ingestion Test Guideline 475
	[oxy(methyl-1,2-etha otoxicity in vitro		decyl)-ω-(phenylmethoxy)-: erial reverse mutation assay (AMES) e
Fluaz	zuron:		
	otoxicity in vitro	: Test Type: Bact Result: negative	erial reverse mutation assay (AMES)
		Test Type: DNA Result: negative	
		Test Type: In vit Result: negative	tro mammalian cell gene mutation test
Geno	otoxicity in vivo	: Test Type: Cyto Species: Hamst Result: equivoca	er
aban	nectin (combination	of avermectin B1a and	l avermectin B1b) (ISO):
Geno	otoxicity in vitro	: Test Type: Bact Result: negative	erial reverse mutation assay (AMES)
			tro mammalian cell gene mutation test ninese hamster lung cells
		Test Type: Alka Result: negative	line elution assay
Genc	otoxicity in vivo	cytogenetic test Species: Mouse	te: Intraperitoneal injection
7-0x	abicyclo[4.1.0]hept-3	3-ylmethyl 7-oxabicvcl	o[4.1.0]heptane-3-carboxylate:
	otoxicity in vitro		tro mammalian cell gene mutation test





	Revision Date: 2021/08/27		OS Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
Genot	oxicity in vivo	:	mammalian live Species: Rat Application Rot	ute: Ingestion Test Guideline 486
			Test Type: Mich Species: Mouse Application Rou Result: negativ	e ute: Intraperitoneal injection
	cell mutagenicity - sment	:	Weight of evide cell mutagen.	ence does not support classification as a gern
2,6-Di	-tert-butyl-p-cresol:			
Genot	oxicity in vitro	:	Test Type: Bac Result: negativ	terial reverse mutation assay (AMES) e
			Test Type: In v Result: negativ	tro mammalian cell gene mutation test e
			Test Type: Chr Result: negativ	omosome aberration test in vitro e
Genot	oxicity in vivo	:		
	nogenicity		· • ·	
Not cla	assified based on avai	lable	information.	
Not cla <u>Comp</u>	assified based on avai ponents:	lable	information.	
Not cla <u>Comp</u> Propa	assified based on avai ponents: n-2-ol:	lable :	information. Rat	
Not cla <u>Comp</u> Propa Specie Applic	assified based on avai conents: un-2-ol: es cation Route	lable :	Rat inhalation (vapo	our)
Not cla <u>Comp</u> Propa Specie Applic Expos	assified based on avai conents: an-2-ol: es ation Route sure time	lable : :	Rat inhalation (vapo 104 weeks	
Not cla <u>Comp</u> Propa Specia Applic Expos Metho	assified based on avai conents: an-2-ol: es sation Route sure time od	lable : :	Rat inhalation (vap 104 weeks OECD Test Gu	
Not cla <u>Comp</u> Propa Specie Applic Expos	assified based on avai conents: an-2-ol: es sation Route sure time od	lable : : :	Rat inhalation (vapo 104 weeks	
Not cla <u>Comp</u> Propa Specie Applic Expos Metho Result N-Met	assified based on avai conents: an-2-ol: es ation Route sure time od t t t	lable : : :	Rat inhalation (vap 104 weeks OECD Test Gu	
Not cla <u>Comp</u> Propa Specia Applic Expos Metho Result N-Met Specia	assified based on avai conents: an-2-ol: es estion Route sure time od t t t t t t t t t	lable : : :	Rat inhalation (vapo 104 weeks OECD Test Gu negative Rat	
Not cla <u>Comp</u> Propa Specie Applic Expos Metho Result N-Met Specie Applic	assified based on avai conents: an-2-ol: es cation Route sure time od t t t t t t t t	lable : : : :	Rat inhalation (vapo 104 weeks OECD Test Gu negative Rat Ingestion	
Not cla <u>Comp</u> Propa Specie Applic Expos Metho Result N-Met Specie Applic	assified based on avai conents: an-2-ol: es ation Route sure time od t t t t t t t t	lable : : : : :	Rat inhalation (vapo 104 weeks OECD Test Gu negative Rat	
Not cla <u>Comp</u> Propa Specie Applic Expos Metho Result Specie Applic Expos	assified based on avai conents: an-2-ol: es ation Route sure time od t t t t t t t t	lable : : : : :	Rat inhalation (vapo 104 weeks OECD Test Gu negative Rat Ingestion 2 Years	






ersion 1	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
Expos Result	ure time	: 2 Years : negative	
Fluazu	iron:		
Specie		: Rat	
	ation Route	: Ingestion	
Expos Metho	ure time	: 2 Years : OECD Test Guide	ling 452
Result		: negative	1116 455
Specie		: Mouse	
	ation Route	: Ingestion	
Expos Result	ure time	: 2 Years	
Result		: negative	
	•	f avermectin B1a and a	vermectin B1b) (ISO):
Specie		: Rat	
	ation Route ure time	: Oral : 105 weeks	
Result		: negative	
		. nogalite	
Specie		: Mouse	
	ation Route	: Oral	
Result	ure time	: 93 weeks : negative	
rteour		. negative	
	tert-butyl-p-cresol:		
Specie		: Rat	
	ation Route ure time	: Ingestion : 22 Months	
Result		: negative	
Repro	ductive toxicity		
•	amage the unborn ch	ld.	
<u>Comp</u>	onents:		
Propa			
Effects	s on fertility		eneration reproduction toxicity study
		Species: Rat Application Route:	Indestion
		Result: negative	ingestion
Effects	on foetal develop-	: Test Type: Embryo	p-foetal development
ment		Species: Rat	-
		Application Route:	Ingestion
		Result: negative	
	hyl-2-pyrrolidone:		
Effects	s on fertility		eneration reproduction toxicity study
		Species: Rat	





ersion .4	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
			Route: Ingestion ECD Test Guideline 416 pative
Effec ment	ts on foetal develop-	Species: R Applicatior	Route: Ingestion ECD Test Guideline 414
		Species: R	Route: inhalation (vapour)
		Species: R	Route: Ingestion
Repro sessr	oductive toxicity - As- nent	: Clear evide animal exp	ence of adverse effects on development, based on eriments.
Fluaz	uron:		
Effec	ts on fertility	Species: R	Route: Ingestion
Effec ment	ts on foetal develop-	Species: R	Route: Ingestion
		Species: R Application	Route: Ingestion ECD Test Guideline 414
abam	nectin (combination o	avermectin B1	a and avermectin B1b) (ISO):
	ts on fertility	: Test Type: Species: R Applicatior	Fertility
		Species: R Application	Route: Oral yonic Development: NOAEL: 0.12 mg/kg body





Abamectin / Fluazuron Formulation

Version 5.4	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
Eff	ects on foetal develop- nt	Species: Mou Application Ro General Toxic Developmenta Result: Cleft p	oute: Oral ity Maternal: NOAEL: 0.05 mg/kg body weight al Toxicity: NOAEL: 0.2 mg/kg body weight
		Species: Rabl Application Ro Developmenta Result: Cleft p survival	
		Test Type: De Species: Rat Application Ro Developmenta Result: Terato	oute: Oral al Toxicity: LOAEL: 1.6 mg/kg body weight
	productive toxicity - As- ssment	fertility, based	ce of adverse effects on sexual function and on animal experiments., Some evidence of ts on development, based on animal experi-
7-0)xabicyclo[4.1.0]hept-3-y	Imethyl 7-oxabicy	clo[4.1.0]heptane-3-carboxylate:
Eff me	ects on foetal develop- nt	Species: Rat Application Re	nbryo-foetal development oute: Ingestion D Test Guideline 414 ve
2,6	-Di-tert-butyl-p-cresol:		
Eff	ects on fertility	Species: Rat	vo-generation reproduction toxicity study oute: Ingestion ve
Eff	ects on foetal develop- nt	Species: Rat	nbryo-foetal development oute: Ingestion ve

STOT - single exposure

May cause respiratory irritation. May cause drowsiness or dizziness.



according to GB/T 16483 and GB/T 17519

rsion	Revision Date: 2021/08/27		OS Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12				
<u>Comp</u>	oonents:							
Prona	an-2-ol:							
-	sment		May cause drov	vsiness or dizziness				
A3363			: May cause drowsiness or dizziness.					
N-Met	thyl-2-pyrrolidone:							
Asses	sment	:	May cause resp	piratory irritation.				
sтот	- repeated exposu	re						
May c	ause damage to org	ans thr	ough prolonged o	or repeated exposure.				
Comp	oonents:							
abam	ectin (combination	of ave	rmectin B1a and	d avermectin B1b) (ISO):				
	sure routes	:	Ingestion					
	t Organs	:	Central nervous					
Asses	sment	:	Causes damage exposure.	e to organs through prolonged or repeated				
2,6-Di	-tert-butyl-p-cresol	:						
Asses	sment	:	No significant h tions of 100 mg	ealth effects observed in animals at concentr /kg bw or less.				
Repea	ated dose toxicity							
-	ated dose toxicity ponents:							
Comp	-							
Comp	oonents: an-2-ol:	:	Rat					
<u>Comp</u> Propa	oonents: an-2-ol: es	:	12.5 mg/l					
Comp Propa Specie NOAE Applic	ponents: an-2-ol: es EL cation Route	:	12.5 mg/l inhalation (vapo	pur)				
Comp Propa Specie NOAE Applic	oonents: an-2-ol: es EL	: : :	12.5 mg/l	pur)				
Comp Propa Specie NOAE Applic Expos	ponents: an-2-ol: es EL cation Route	: : : : : : : : : : : : : : : : : : : :	12.5 mg/l inhalation (vapo	pur)				
Comp Propa Specia NOAE Applic Expose N-Met Specia	oonents: an-2-ol: es EL cation Route sure time thyl-2-pyrrolidone: es		12.5 mg/l inhalation (vapo 104 Weeks Rat, male	pur)				
Comp Propa Specia NOAE Applic Expose N-Met Specia NOAE	an-2-ol: es EL cation Route sure time thyl-2-pyrrolidone: es EL		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg	pur)				
Comp Propa Specie NOAE Applic Expose NOAE Specie NOAE LOAE	conents: an-2-ol: es EL cation Route sure time thyl-2-pyrrolidone: es EL L		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg	pur)				
Comp Propa Specie NOAE Applic Expose NOAE NOAE LOAE Applic	conents: an-2-ol: es EL cation Route sure time thyl-2-pyrrolidone: es EL L cation Route		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion	pur)				
Comp Propa Specie NOAE Applic Expose N-Met Specie NOAE LOAE Applic Expose	conents: an-2-ol: es EL cation Route sure time thyl-2-pyrrolidone: es EL L cation Route sure time		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days					
Comp Propa Specie NOAE Applic Expose NOAE NOAE LOAE Applic	conents: an-2-ol: es EL cation Route sure time thyl-2-pyrrolidone: es EL L cation Route sure time		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion					
Comp Propa Specie NOAE Applic Expose NOAE LOAE Applic Expose Methor Specie	ponents: an-2-ol: es EL pation Route sure time thyl-2-pyrrolidone: es EL L sation Route sure time od		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days OECD Test Gu Rat					
Comp Propa Specia NOAE Applic Expose NOAE LOAE Applic Expose Metho Specia NOAE	ponents: an-2-ol: es EL sation Route sure time thyl-2-pyrrolidone: es EL L sation Route sure time od es EL		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days OECD Test Gu Rat 0.5 mg/l					
Comp Propa Specia NOAE Applic Expose NOAE LOAE Applic Expose Metho Specia NOAE LOAE	ponents: an-2-ol: es EL eation Route sure time thyl-2-pyrrolidone: es EL L sation Route sure time od es EL L		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days OECD Test Gu Rat 0.5 mg/l 1 mg/l	ideline 408				
Comp Propa Specia NOAE Applic Expose NOAE LOAE Applic Expose Metho Specia NOAE LOAE Applic Expose Metho	an-2-ol: es EL estion Route sure time thyl-2-pyrrolidone: es EL L eation Route sure time od es EL L eation Route sure time ad		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days OECD Test Gu Rat 0.5 mg/l 1 mg/l inhalation (dust	ideline 408				
Comp Propa Specia NOAE Applic Expose NOAE LOAE Applic Expose Metho Specia NOAE LOAE Applic Expose Metho	an-2-ol: es EL estion Route sure time thyl-2-pyrrolidone: es EL L eation Route sure time od es EL L eation Route sure time ad		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days OECD Test Gu Rat 0.5 mg/l 1 mg/l	ideline 408 /mist/fume)				
Comp Propa Specie NOAE Applic Expose N-Met Specie NOAE LOAE Applic Expose Metho Specie NOAE LOAE Applic Expose Metho Expose Metho	ponents: an-2-ol: es EL pation Route sure time thyl-2-pyrrolidone: es EL L bation Route sure time od es EL L bation Route sure time od es EL L bation Route sure time od		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days OECD Test Gu Rat 0.5 mg/l 1 mg/l inhalation (dust 96 Days OECD Test Gu Rabbit	ideline 408 /mist/fume)				
Comp Propa Specie NOAE Applic Expose NOAE LOAE Applic Expose Metho Expose Metho	ponents: an-2-ol: es EL pation Route sure time thyl-2-pyrrolidone: es EL L bation Route sure time od es EL L bation Route sure time od es EL L bation Route sure time od		12.5 mg/l inhalation (vapo 104 Weeks Rat, male 169 mg/kg 433 mg/kg Ingestion 90 Days OECD Test Gu Rat 0.5 mg/l 1 mg/l inhalation (dust 96 Days OECD Test Gu	ideline 408 /mist/fume)				

according to GB/T 16483 and GB/T 17519




ersion 4	Revision Date: 2021/08/27	SDS Number: 800398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
Applic	cation Route	: Skin contact	
	sure time	: 20 Days	
Fluaz	uron:		
Speci		: Rat	
LOAE		: 240 mg/kg	
	ation Route	: Ingestion	
	sure time	: 13 Weeks	
	t Organs	: Liver, Thyroid,	Pituitary gland
Speci		: Rat	
NOAE		: 10 mg/kg	
LOAE		: 100 mg/kg	
	cation Route	: Skin contact	
Expos	sure time	: 3 Weeks	
Speci		: Dog	
NOAE		: 7.5 mg/kg	
LOAE		: 110 mg/kg	
	cation Route sure time	: Ingestion : 52 Weeks	
	t Organs	: Liver	
abam	ectin (combination	of avermectin B1a an	d avermectin B1b) (ISO):
Speci NOAE Applic Expos	es EL cation Route sure time t Organs	of avermectin B1a an : Rat : 1.5 mg/kg : Oral : 24 Months : Central nervou : Tremors, ataxia	
Speci NOAE Applic Expos Targe Symp	es EL cation Route sure time t Organs toms	: Rat : 1.5 mg/kg : Oral : 24 Months : Central nervou : Tremors, ataxia	s system
Speci NOAE Applic Expos Targe Symp Speci	es EL cation Route sure time it Organs toms es	: Rat : 1.5 mg/kg : Oral : 24 Months : Central nervou : Tremors, ataxis : Mouse	s system
Speci NOAE Applic Expos Targe Symp Speci NOAE	es EL cation Route sure time it Organs toms es EL	: Rat : 1.5 mg/kg : Oral : 24 Months : Central nervou : Tremors, ataxis : Mouse : 4.0 mg/kg	s system
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic	es EL cation Route sure time it Organs toms es EL cation Route	: Rat : 1.5 mg/kg : Oral : 24 Months : Central nervou : Tremors, ataxis : Mouse : 4.0 mg/kg : Oral	s system
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos	es EL cation Route sure time it Organs toms es EL	: Rat : 1.5 mg/kg : Oral : 24 Months : Central nervou : Tremors, ataxis : Mouse : 4.0 mg/kg	s system a
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos	es EL cation Route sure time it Organs toms es EL cation Route sure time it Organs	: Rat : 1.5 mg/kg : Oral : 24 Months : Central nervou : Tremors, ataxis : Mouse : 4.0 mg/kg : Oral : 24 Months	s system a s system
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Targe Symp	es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Contral nervou Tremors, ataxis 	s system a s system
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Targe Symp Speci NOAE	es EL cation Route sure time torgans toms es EL cation Route sure time torgans toms es EL	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Dog 0.25 mg/kg 	s system a s system
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Targe Symp Speci NOAE LOAE	es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es EL cat	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Dog 0.25 mg/kg 0.5 mg/kg 	s system a s system
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Targe Symp Speci NOAE LOAE Applic	es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es EL cation Route	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Dog 0.25 mg/kg 0.5 mg/kg Oral Oral 	s system a s system
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Targe Symp Speci NOAE LOAE Applic Expos	es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es EL cation Route sure time cation Route sure time	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks 	s system a s system a
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Symp Speci NOAE LOAE Applic Expos Targe	es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es EL cation Route sure time cation Route sure time to Organs	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks Central nervou 	s system a s system a s system
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Targe Symp Speci NOAE LOAE Applic Expos	es EL cation Route sure time at Organs toms es EL cation Route sure time at Organs toms es EL cation Route sure time torgans toms es EL cation Route sure time to Organs toms	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks 	s system a s system a s system ht loss
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Speci NOAE LOAE Applic Expos Targe Symp Rema	es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxia Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxia Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks Central nervou Tremors, weigl mortality obser 	s system a s system a s system ht loss
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Symp Speci NOAE LOAE Applic Expos Targe Symp	es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks Central nervou Tremors, weigl mortality obsers Monkey 	s system a s system a s system ht loss
Speci NOAE Applic Expos Symp Speci NOAE Applic Expos Symp Speci NOAE LOAE Applic Expos Targe Symp Rema	es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es EL cation Route sure time t Organs toms es	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxia Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxia Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks Central nervou Tremors, weigl mortality obser 	s system a s system a s system ht loss
Speci NOAE Applic Expos Targe Symp Speci NOAE Applic Expos Targe Symp Speci NOAE LOAE Applic Expos Targe Symp Rema	es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es EL cation Route sure time to Organs toms es	 Rat 1.5 mg/kg Oral 24 Months Central nervou Tremors, ataxis Mouse 4.0 mg/kg Oral 24 Months Central nervou Tremors, ataxis Dog 0.25 mg/kg 0.5 mg/kg Oral 53 Weeks Central nervou Tremors, weigl mortality obsert Monkey 1.0 mg/kg 	s system a s system a s system ht loss



according to GB/T 16483 and GB/T 17519

ersion .4	Revision Date: 2021/08/27		0S Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
Spec NOA Appli		:	Rat 25 mg/kg Ingestion 22 Months	
-	ration toxicity lassified based on availa	ble	information.	
Expe	rience with human exp	osi	ire	
<u>Com</u>	ponents:			
Skin	ethyl-2-pyrrolidone: contact	:	Symptoms: Skin i	
Inges	nectin (combination of a stion	ave :		cause, Tremors, Diarrhoea, central nervous
2. ECOL	OGICAL INFORMATION	N		
Ecot	oxicity			
<u>Com</u>	ponents:			
Prop	an-2-ol:			
Toxic	ity to fish	:	LC50 (Pimephale Exposure time: 96	s promelas (fathead minnow)): 9,640 mg/l S h
	ity to daphnia and other tic invertebrates	:	EC50 (Daphnia m Exposure time: 24	nagna (Water flea)): > 10,000 mg/l 4 h
Toxic	ity to microorganisms	:	EC50 (Pseudomo Exposure time: 16	nas putida): > 1,050 mg/l 5 h
N-Me	thyl-2-pyrrolidone:			
	ity to fish	:	LC50 (Oncorhync Exposure time: 96	hus mykiss (rainbow trout)): > 500 mg/l 5 h
	ity to daphnia and other tic invertebrates	:	EC50 (Daphnia m Exposure time: 24 Method: DIN 384	
Toxic plants	ity to algae/aquatic s	:	ErC50 (Desmode Exposure time: 72	smus subspicatus (green algae)): 600.5 mg 2 h
			EC10 (Desmodes Exposure time: 72	mus subspicatus (green algae)): 92.6 mg/l 2 h
	ity to daphnia and other tic invertebrates (Chron- icity)	:	NOEC (Daphnia r Exposure time: 2 Method: OECD T	






Version 5.4	Revision Date: 2021/08/27		9S Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
Toxici	ity to microorganisms	:	EC50: > 600 mg/l Exposure time: 30 Method: ISO 8192) min
		diyl		ecyl)-ω-(phenylmethoxy)-:
Toxici	ity to fish	:	LC50: 540 mg/l Exposure time: 96 Test substance: V	6 h Vater Accommodated Fraction
	ity to daphnia and other ic invertebrates	:	Exposure time: 48	nia dubia (water flea)): 221 mg/l 3 h Vater Accommodated Fraction
Toxici plants	ity to algae/aquatic	:	NOEC (Selenastro mg/l Exposure time: 72 Method: OECD To	
Fluaz	uron:			
Toxici	ity to fish	:	LC50 (Cyprinus ca Exposure time: 96	arpio (Carp)): > 9.1 mg/l S h
	ity to daphnia and other ic invertebrates	:	EC50 (Daphnia s Exposure time: 48	o. (water flea)): 0.0006 mg/l 3 h
Toxici plants	ity to algae/aquatic	:	NOEC (Raphidoc 27.9 mg/l Exposure time: 72	elis subcapitata (freshwater green alga)): 2 h
	ctor (Acute aquatic tox-	:	1,000	
icity) M-Fao toxicit	ctor (Chronic aquatic y)	:	1,000	
	ectin (combination of a ity to fish	ave :		hus mykiss (rainbow trout)): 3.2 μg/l
			LC50 (Lepomis m Exposure time: 96	acrochirus (Bluegill sunfish)): 9.6 µg/l 5 h
			LC50 (Ictalurus pu Exposure time: 96	unctatus (channel catfish)): 24 μg/l δ h
			LC50 (Cyprinus ca Exposure time: 96	arpio (Carp)): 42 μg/l δ h
			LC50 (Cyprinodor Exposure time: 96	n variegatus (sheepshead minnow)): 15 μg/l δ h
	ity to daphnia and other ic invertebrates	:	EC50 (Americamy Exposure time: 96	

according to GB/T 16483 and GB/T 17519




ersion .4	Revision Date: 2021/08/27		9S Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
			EC50 (Daphnia n Exposure time: 4	nagna (Water flea)): 0.34 μg/l 3 h
Toxici plants	ty to algae/aquatic	:	EC50 (Pseudokir mg/l Exposure time: 72	chneriella subcapitata (green algae)): 100 2 h
M-Fac icity)	ctor (Acute aquatic tox-	:	10,000	
	ty to fish (Chronic tox-	:	NOEC (Pimephal Exposure time: 3	es promelas (fathead minnow)): 0.52 μg/l 2 d
aquat	ty to daphnia and other ic invertebrates (Chron-	:	NOEC (Daphnia Exposure time: 2	magna (Water flea)): 0.03 μg/l 1 d
ic toxi	Сіту)		NOEC (Mysidops Exposure time: 2	is bahia (opossum shrimp)): 0.0035 μg/l 3 d
M-Fac toxicit	ctor (Chronic aquatic	:	10,000	
	y) ty to microorganisms	:	EC50: > 1,000 m Exposure time: 3 Test Type: Respi	h
7-0xa	abicyclo[4.1.0]hept-3-y	lme	thyl 7-oxabicyclo	[4.1.0]heptane-3-carboxylate:
	ity to fish	:	LC50 (Oncorhynd Exposure time: 9	chus mykiss (rainbow trout)): 24 mg/l
	ty to daphnia and other ic invertebrates	:	Exposure time: 4	nagna (Water flea)): 40 mg/l 3 h est Guideline 202
Toxici plants	ty to algae/aquatic	:	ErC50 (Selenastr Exposure time: 7: Method: OECD T	
			Exposure time: 72	um capricornutum (green algae)): 30 mg/l 2 h est Guideline 201
Toxici	ty to microorganisms	:	Exposure time: 3	croorganism): 409 mg/l h est Guideline 209
2,6-D	i-tert-butyl-p-cresol:			
	ity to fish	:	Exposure time: 9	
			Method: Directive	e 67/548/EEC, Annex V, C.1.





	Revision Date: 2021/08/27		0S Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
			Method: OECD To	est Guideline 202
Toxici plants	ty to algae/aquatic	:	ErC50 (Pseudokir mg/l Exposure time: 72 Method: OECD To	
			NOEC (Pseudokin mg/l Exposure time: 72 Method: OECD Te	
	ctor (Acute aquatic tox-	:	1	
icity) Toxici icity)	ty to fish (Chronic tox-	:	NOEC (Oryzias la Exposure time: 30 Method: OECD Te	
	ty to daphnia and other ic invertebrates (Chron- city)	:	NOEC (Daphnia r Exposure time: 21	nagna (Water flea)): 0.316 mg/l I d
	ctor (Chronic aquatic	:	1	
	ty to microorganisms	:	EC50: > 10,000 m Exposure time: 3 Method: OECD Te	ĥ
Persis	stence and degradabili	ity		
	stence and degradabili	ty		
<u>Comp</u> Propa	_	ity :	Result: rapidly de	gradable
<u>Comp</u> Propa	ponents: an-2-ol: gradability	i ty :		gradable 5)COD: 2.23BOD/COD: 53 %
Comp Propa Biodeg BOD/(oonents: an-2-ol: gradability COD	i ty :		-
Comp Propa Biode BOD/0	ponents: an-2-ol: gradability	i ty : :	BOD: 1.19 (BOD5 Result: Readily bi	5)COD: 2.23BOD/COD: 53 % odegradable.
Comp Propa Biode BOD/0	oonents: m-2-ol: gradability COD :hyl-2-pyrrolidone:	:	BOD: 1.19 (BOD5	5)COD: 2.23BOD/COD: 53 % odegradable. 73 %
Comp Propa Biode BOD/0	oonents: m-2-ol: gradability COD :hyl-2-pyrrolidone:	:	BOD: 1.19 (BOD5 Result: Readily bi Biodegradation: 7 Exposure time: 28	5)COD: 2.23BOD/COD: 53 % odegradable. 73 %
Comp Propa Biodeg BOD/0 N-Met Biodeg	oonents: m-2-ol: gradability COD :hyl-2-pyrrolidone:	: :	BOD: 1.19 (BOD5 Result: Readily bi Biodegradation: 7 Exposure time: 28 Method: OECD To	5)COD: 2.23BOD/COD: 53 % odegradable. 73 % 3 d est Guideline 301C
Comp Propa Biodeg BOD/0 N-Met Biodeg	ponents: an-2-ol: gradability COD thyl-2-pyrrolidone: gradability	: : :	BOD: 1.19 (BOD5 Result: Readily bi Biodegradation: 7 Exposure time: 28 Method: OECD To	5)COD: 2.23BOD/COD: 53 % odegradable. 73 % 3 d est Guideline 301C avermectin B1b) (ISO):
Comp Propa Biodeg BOD/0 N-Met Biodeg	ectin (combination of a	: : : :	BOD: 1.19 (BOD5 Result: Readily bi Biodegradation: 7 Exposure time: 28 Method: OECD To rmectin B1a and a Hydrolysis: 50 %(5)COD: 2.23BOD/COD: 53 % odegradable. 73 % 3 d est Guideline 301C avermectin B1b) (ISO):
Comp Propa Biode BOD/C N-Met Biode Stabili	ectin (combination of a	: : : :	BOD: 1.19 (BODS Result: Readily bi Biodegradation: 7 Exposure time: 28 Method: OECD To rmectin B1a and a Hydrolysis: 50 %(thyl 7-oxabicyclo Biodegradation: 7 Exposure time: 28	5)COD: 2.23BOD/COD: 53 % odegradable. 73 % 3 d est Guideline 301C evermectin B1b) (ISO): < 12 h) (4.1.0]heptane-3-carboxylate: 71 %





/ersion 5.4	Revision Date: 2021/08/27		OS Number: 0398-00018	Date of last issue: 2021/04/26 Date of first issue: 2016/07/12
2,6-Di	-tert-butyl-p-cresol:			
Biode	gradability	:	Biodegradation: Exposure time:	
Bioad	cumulative potential			
Comp	oonents:			
Propa	an-2-ol:			
	on coefficient: n- ol/water	:	log Pow: 0.05	
N-Met	thyl-2-pyrrolidone:			
	on coefficient: n- ol/water	:		Test Guideline 107
Fluaz	uron:			
	on coefficient: n- ol/water	:	log Pow: 5.1	
abam	ectin (combination o	f ave	rmectin B1a and	d avermectin B1b) (ISO):
Bioac	cumulation	:	Bioconcentratio	n factor (BCF): 52
	on coefficient: n- ol/water	:	log Pow: 4	
7-Oxa	bicyclo[4.1.0]hept-3-	ylme	thyl 7-oxabicycl	o[4.1.0]heptane-3-carboxylate:
	on coefficient: n- ol/water	:	log Pow: 1.34	
2,6-Di	-tert-butyl-p-cresol:			
Bioac	cumulation	:		us carpio (Carp) n factor (BCF): 330 - 1,800
	on coefficient: n- ol/water	:	log Pow: 5.1	
Mobil	ity in soil			
Comp	oonents:			
abam	ectin (combination o	f ave	rmectin B1a and	d avermectin B1b) (ISO):
	oution among environ- al compartments	:	log Koc: > 3.6	
	adverse effects ta available			

according to GB/T 16483 and GB/T 17519



Abamectin / Fluazuron Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2021/04/26
5.4	2021/08/27	800398-00018	Date of first issue: 2016/07/12

13. DISPOSAL CONSIDERATIONS

Disposal methods

Waste from residues	:	Dispose of in accordance with local regulations.		
Contaminated packaging	 Empty containers should be taken to an approved wast dling site for recycling or disposal. 			
		Empty containers retain residue and can be dangerous.		
		Do not pressurize, cut, weld, braze, solder, drill, grind, or ex-		
		pose such containers to heat, flame, sparks, or other sources		
		of ignition. They may explode and cause injury and/or death.		
		If not otherwise specified: Dispose of as unused product.		

14. TRANSPORT INFORMATION

International Regulations

UNRTDG UN number Proper shipping name Class Packing group Labels	UN 1993 FLAMMABLE LIQUID, N.O.S. (Propan-2-ol) 3 III 3		
IATA-DGR UN/ID No. Proper shipping name	UN 1993 Flammable liquid, n.o.s. (Propan-2-ol)		
Class Packing group Labels Packing instruction (cargo aircraft)	3 III Flammable Liquids 366		
ger aircraft)	355		
IMDG-Code UN number Proper shipping name	UN 1993 FLAMMABLE LIQUID, N.O.S. (Propan-2-ol, Fluazuron, abamectin (combination of avermec- tin B1a and avermectin B1b) (ISO))		
Class Packing group Labels EmS Code Marine pollutant	3 III 3 F-E, <u>S-E</u> yes		
Transport in bulk according to Annex II of MARPOL 73/78 and the IBC Code Not applicable for product as supplied.			

National Regulations

GB 6944/12268

UN number	:	UN 1993
Proper shipping name	:	FLAMMABLE LIQUID, N.O.S.

Revision Date:

2021/08/27

Version

5.4



Date of last issue: 2021/04/26

Date of first issue: 2016/07/12

Abamectin / Fluazuron Formulation

SDS Number:

800398-00018

		(Propan-2-ol)	
Class	:	3	, ,	
Packing group	:	111		
Labels	:	3		
Special preca	utions for user			
based upon th Sheet. Transp	e properties of the	unpackaged m ions may vary b	re for informational purposes only, naterial as it is described within this by mode of transportation, package	Safety Data
15. REGULATORY	INFORMATION			
-	latory informatio revention and Co		ational Diseases	
Regulations of	on Safety Manage	ment of Hazar	dous Chemicals	
-	lazardous Chemic		: Listed	
Identification o	f Major Hazard Ins	stallations for H	azardous Chemicals (GB 18218)	
No. / Code	Chemical nam	ne / Category	Threshold quantity	
W5.4	Flammable liq	uids	5,000 t	
The compone	nts of this produ	ct are reported	d in the following inventories:	
-	ints of this produ	-	-	
AICS	:	not determine	€d	
DSL	:	not determine	эd	
IECSC	:	not determine	эd	
16. OTHER INFOR				
10. OTHER INFOR	MATION			
Further inform	nation			
Sources of key	/ data used to :	Internal techr	nical data, data from raw material S	SDSs OFCD
compile the Sa			I search results and European Che	
Sheet		cy, http://echa	•	initiality right
Date format	:	yyyy/mm/dd		
Full text of ot	her abbreviations	6		
ACGIH		USA, ACGIH	Threshold Limit Values (TLV)	
ACGIH BEI	:		ogical Exposure Indices (BEI)	
CN OEL	:		exposure limits for hazardous age	ents in the
0022	•		New 'set the set of the set of the	

	······
ACGIH / TWA	: 8-hour, time-weighted average
ACGIH / STEL	: Short-term exposure limit
CN OEL / PC-TWA	: Permissible concentration - time weighted average
CN OEL / PC-STEL	: Permissible concentration - short term exposure limit

AIIC - Australian Inventory of Industrial Chemicals; ANTT - National Agency for Transport by Land of Brazil; ASTM - American Society for the Testing of Materials; bw - Body weight; CMR -

workplace - Chemical hazardous agents.



Abamectin / Fluazuron Formulation

Version	Revision Date:	SDS Number:	Date of last issue: 2021/04/26
5.4	2021/08/27	800398-00018	Date of first issue: 2016/07/12

Carcinogen, Mutagen or Reproductive Toxicant; DIN - Standard of the German Institute for Standardisation; DSL - Domestic Substances List (Canada); ECx - Concentration associated with x% response; ELx - Loading rate associated with x% response; EmS - Emergency Schedule; ENCS - Existing and New Chemical Substances (Japan); ErCx - Concentration associated with x% growth rate response; ERG - Emergency Response Guide; GHS - Globally Harmonized System; GLP - Good Laboratory Practice; IARC - International Agency for Research on Cancer; IATA - International Air Transport Association; IBC - International Code for the Construction and Equipment of Ships carrying Dangerous Chemicals in Bulk; IC50 - Half maximal inhibitory concentration; ICAO - International Civil Aviation Organization; IECSC - Inventory of Existing Chemical Substances in China; IMDG - International Maritime Dangerous Goods; IMO - International Maritime Organization; ISHL - Industrial Safety and Health Law (Japan); ISO - International Organisation for Standardization; KECI - Korea Existing Chemicals Inventory; LC50 - Lethal Concentration to 50 % of a test population; LD50 - Lethal Dose to 50% of a test population (Median Lethal Dose); MARPOL - International Convention for the Prevention of Pollution from Ships; n.o.s. - Not Otherwise Specified; Nch - Chilean Norm; NO(A)EC - No Observed (Adverse) Effect Concentration; NO(A)EL - No Observed (Adverse) Effect Level; NOELR - No Observable Effect Loading Rate; NOM - Official Mexican Norm; NTP - National Toxicology Program; NZIoC - New Zealand Inventory of Chemicals; OECD - Organization for Economic Co-operation and Development; OPPTS - Office of Chemical Safety and Pollution Prevention; PBT - Persistent, Bioaccumulative and Toxic substance; PICCS - Philippines Inventory of Chemicals and Chemical Substances; (Q)SAR - (Quantitative) Structure Activity Relationship; REACH - Regulation (EC) No 1907/2006 of the European Parliament and of the Council concerning the Registration, Evaluation, Authorisation and Restriction of Chemicals; SADT - Self-Accelerating Decomposition Temperature; SDS - Safety Data Sheet; TCSI - Taiwan Chemical Substance Inventory; TDG - Transportation of Dangerous Goods; TECI - Thailand Existing Chemicals Inventory; TSCA - Toxic Substances Control Act (United States); UN - United Nations; UNRTDG - United Nations Recommendations on the Transport of Dangerous Goods; vPvB - Very Persistent and Very Bioaccumulative; WHMIS - Workplace Hazardous Materials Information System

Disclaimer

The information provided in this Safety Data Sheet is correct to the best of our knowledge, information and belief at the date of its publication. The information is designed only as a guidance for safe handling, use, processing, storage, transportation, disposal and release and shall not be considered a warranty or quality specification of any type. The information provided relates only to the specific material identified at the top of this SDS and may not be valid when the SDS material is used in combination with any other materials or in any process, unless specified in the text. Material users should review the information and recommendations in the specific context of their intended manner of handling, use, processing and storage, including an assessment of the appropriateness of the SDS material in the user's end product, if applicable.

CN / EN